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Abstract
Background: The Q705K polymorphism in NLRP3 has been implicated in several chronic inflammatory diseases. In this study
we determine the functional role of this commonly occurring polymorphism using an in-vitro system.
Principal Findings: NLRP3-WT and NLRP3-Q705K were retrovirally transduced into the human monocytic cell line THP-1,
followed by the assessment of IL-1b and IL-18 levels in the cell culture supernatant. THP-1 cells expressing the above NLRP3
variants were sorted based upon Green Fluorescent Protein (GFP) expression. Cytokine response to alum (one of the most
widely used adjuvants in vaccines) in the cells stably expressing NLRP3-WT and NLRP3-Q705K were determined. IL-1b and
IL-18 levels were found to be elevated in THP-1 cells transduced with NLRP3-Q705K compared to the NLRP3-WT. Upon
exposure to alum, THP-1 cells stably expressing NLRP3-Q705K displayed an increased release of IL-1b, IL-18 and TNF-a,i na
caspase-1 and IL-1 receptor-dependent manner.
Conclusions: Collectively, these findings show that the Q705K polymorphism in NLRP3 is a gain-of-function alteration
leading to an overactive NLRP3 inflammasome. The option of IL-1b blockade may be considered in patients with chronic
inflammatory disorders that are unresponsive to conventional treatments.
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Introduction
Inflammasomes are essential regulators of interleukin (IL)-1b
production. Upon activation, NLRP3 (formerly known as
Cryopyrin/CIAS1/NALP3), associates with ASC (PYCARD)
adaptor and pro-caspase-1 to form the NLRP3 inflammasome.
This interaction leads to the activation of caspase-1, which
proteolytically processes pro-IL-1b and pro-IL-18 to form active
IL-1b and IL-18 [1]. CARD-8 has been suggested to be a binding
partner of the inflammasome [2] but its role in the inflammasome
is still a matter of debate. Gain-of-function mutations in the gene
encoding NLRP3 can lead to its constitutive activation resulting in
an uncontrolled IL-1b production. NLRP3 mutations have been
implicated in hereditary inflammatory diseases and are grouped
under cryopyrin-associated periodic syndromes (CAPS) or cryo-
pyrinopathies [3]. The CAPS are regarded as monogenic
disorders, comprising a trio of autoinflammatory conditions
varying in severity of disease manifestation: familial cold associated
syndrome (FCAS) being the mildest form, Muckle-Wells syndrome
(MWS) being intermediate, and neonatal onset multisystem
disorder (NOMID, also known as chronic infantile neurological
cutaneous and articular syndrome; CINCA), being the most
severe. Patients suffering from these syndromes typically present
with fever, skin rashes and arthritis-like symptoms. IL-1b plays a
central role in the pathogenesis of these disorders, which is proved
by the remarkable improvement in symptoms upon IL-1b
blockade [4].
We previously reported a patient with chronic inflammatory
symptoms carrying the gene polymorphisms Q705K in NLRP3
(reported in the infevers database as Q703K (http://fmf.igh.cnrs.
fr/ISSAID/infevers/) and C10X in CARD-8 [6]. This patient had
a long history of arthritis and antibiotic-resistant fever but lacked
the typical signs of FCAS, MWS or NOMID. Remarkably, like in
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anakinra effectively abolished the patient’s symptoms. The
abundance of this polymorphism in the general population (5–
11%) [5] makes it highly relevant to study its functional
significance, particularly since several studies have shown a
correlation of Q705K alone or in conjunction with C10X with
increased risk of chronic inflammation [7,8,9,10,11]. Our results
reveal a gain-of-function phenotype of the Q705K polymorphism
which, unlike the other known genetic alterations in NLRP3, is
associated with only moderately increased IL-1b levels. These
findings combined with above epidemiological data are indicative
of an important role of this polymorphism in susceptibility to
chronic inflammatory conditions. Our findings also provide insight
into the requirement of effective IL-1R activation for efficient IL-
1b production in cells with overactive inflammasomes, demon-
strating an autocrine feedback loop for IL-1b release under sterile
conditions.
Results
Enhanced IL-1b and IL-18 release in THP-1 cells
retrovirally transduced with NLRP3-Q705K
To determine whether the Q705K variant of NLRP3 led to a
spontaneous cytokine production, the cells were transduced with a
retroviral vector expressing NLRP3-wild type (WT) or NLRP3-
Q705K. The MWS-associated mutation NLRP3-R260W was
used as a positive control and the empty vector (EV) was used as
negative control. IL-1b, IL-18 and TNF-a levels were measured
48 h after retroviral transduction. Cells expressing NLRP3-
Q705K demonstrated a five-fold increase in IL-1b levels as
compared to the WT control, indicating that this variant leads to a
constitutively activated inflammasome (Fig. 1A). The NLRP3-
R260W variant displayed a seven-fold increase as compared to the
WT control. The use of the caspase-1 inhibitor Z-YVAD-FMK
with NLRP3-Q705K-expressing cells during the 48 hour time
period resulted in IL-1b levels reduced to 47% (data not shown)
demonstrating that this process is to a large extent dependent on
caspase-1. The transduced cells were expressing GFP, the
fluorescence of which was used to determine the transduction
efficiency using flow cytometry (Fig. 1A inset). Correction of the IL-
1b levels for the number of GFP-positive cells rendered data
showing a similar trend, with the Q705K variant inducing higher
levels of IL-1b than the NLRP3- WT (Fig. 1B). IL-18 levels were
also found to be elevated in samples transduced with NLRP3-
Q705K and NLRP3-R260W (Fig. 1C; GFP-corrected data). The
TNF-a levels in all samples were below the detection level at this
early time point after transduction.
NLRP3-Q705K is a gain-of-function alteration
To obtain a population of cells stably expressing the wild type
and mutant variants of NLRP3, we sorted the THP-1 cells
expressing GFP and expanded them in culture medium. Next, in
order to determine the production of cytokines in resting and
stimulated THP-1 expressing NLRP3-Q705K, PMA-differentiat-
ed cells were stimulated with alum, which is one of the most widely
used adjuvants in vaccines [12] and known to trigger sterile
inflammation through the NLRP3 inflammasome [13,14,15].
Alum exposure resulted in a substantial increase in IL-1b
production (Fig. 2A) in THP-1 expressing NLRP3-WT and the
two mutant variants, the latter ones giving a more pronounced
response (Fig. 2A). The NLRP3-Q705K displayed a statistically
significant two-fold increase compared to WT expressing cells
(Fig. 2A inset). A similar trend was observed in IL-18 levels upon
alum stimulation, where NLRP3-Q705K and -R260W-expressing
Figure 1. Basal levels of cytokine production by NLRP3-
tranduced THP-1 cells. THP-1 cells were transduced with NLRP3-
Q705K, NLRP3-R260W, NLRP-3 WT or Empty Vector (EV, i.e. no NLRP3) all
including the gene for GFP. A, IL-1b secretion was determined 48 h
after transduction using ELISA, Inset, Retroviral transduction efficiency
was determined by monitoring GFP expression using flow cytometry. B,
IL-1b determined in A was corrected for the number of GFP+ cells in
culture. C, IL-18 secretion was determined 48 h after transduction and
corrected for GFP+ cells in culture. A–C, Data represents one of three
independent experiments. Experiment was performed in triplicates and
represented as Mean 6 SEM.
doi:10.1371/journal.pone.0034977.g001
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THP-1 cells (Fig. 2B and 2B inset). This demonstrates that the
Q705K variant of NLRP3 leads to an enhanced basal and
stimulated inflammatory response and thus is a gain-of-function
alteration resulting in a more pronounced cytokine production
under sterile conditions, both in unchallenged THP-1 cells and in
response to alum.
The alum-induced IL-1b and IL-18 release by Q705K is
caspase-1 and IL-1R-dependent
To confirm the specificity of our system, we tested whether the
IL-1b and IL-18 production was dependent on caspase-1, which
has been shown to be crucial for production of the studied
cytokines in recent reports [13,14]. Figure 2 shows a remarkable
decrease in cytokine levels upon treatment with the caspase-1-
inhibitor Z-YVAD-FMK, indicating that alum induces a caspase-
1-dependent IL-1b and IL-18 release. It is well established that
TLR ligands enhance the production of pro-IL-1b via NF-kB
activation, and such microbial ligands are therefore widely used in
in vitro studies to enhance IL-1b secretion. Given the fact that
TLRs and the IL-1R share the same signalling pathway for NF-kB
activation [16,17], we investigated to what extent the IL-1R was
required for the observed cytokine production using anakinra in
our sterile setting. Anakinra is a recombinant IL-1R antagonist,
which competitively binds to the IL-1R and blocks downstream
IL-1b signalling [18]. As shown in Figure 2, a substantial decrease
in both IL-1b and IL-18 production was seen after anakinra
treatment of both NLRP3-WT and -Q705K-expressing THP-1
cells showing that the production of both cytokines in response to a
sterile stimulus like alum involves an autocrine positive feedback
mechanism via the IL-1R.
Generally upregulated cytokine levels in patients with mutated
NLRP3 have been shown [19] and in line with this observation we
could detect elevated TNF-a levels in THP-1 cells stably
expressing WT and mutant NLRP3 (Fig. 2C). A substantial
increase in secreted TNF-a levels in alum-stimulated transduced
samples could be observed, however, there were no significant
difference between alum-stimulated NLRP3-WT- and -Q705K-
expressing THP-1 cells (n=4) (Fig. 2C inset). Our observation that
a substantial decrease in TNF-a levels was obtained with Z-
YVAD-FMK and anakinra treatment suggests that the release of
IL-1b triggers TNF-a release via binding to the IL-1R. These two
cytokines have previously been shown to correlate with each other
[20,21,22] but the underlying mechanism is not clearly under-
stood. To corroborate our findings made with the ELISA assays,
we performed a quantitative real-time PCR. As expected, the
mRNA levels of pro-IL-1b were found to be significantly higher in
NLRP3-Q705K as compared to NLRP3-WT (Figure 3A). TNF-a
mRNA levels were also significantly increased in the NLRP3-
Q705K (Figure 3B). These data suggest that the NLRP3-Q705K,
likely through enhanced secretion of IL-1b, up-regulates expres-
sion levels of both pro-IL-1b and TNF-a. In order to determine if
the enhanced expression levels are regulated by IL-1R, we used
anakinra. However, the expression levels of these genes were not
affected by anakinra treatment (data not shown), suggesting that
the mechanism behind transcriptional regulation of IL-1b and
TNF-a must be different from the IL-1R regulated release of these
cytokines.
Discussion
In our previous report of a patient with recurrent inflammatory
symptoms, Q705K in NLRP3 and C10X in CARD-8 were found
to coincide with increased caspase-1 activity and IL-1b secretion
[6]. Our and others’ earlier published epidemiological data
obtained from studies of patients with rheumatoid arthritis and
Crohn’s disease pointed towards a role for this polymorphism in
susceptibility to chronic inflammatory conditions [8,9,10].
We undertook these studies with the aim of evaluating the role
of Q705K in IL-1b production. The human monocytic cell line
THP-1 was used, since it expresses all the components of the
NLRP3 inflammasome [23,24] and does not carry the NLRP3-
Q705K alteration. In addition, this cell line is heterozygous for the
C10X in CARD-8, which makes it a suitable model to study the
effect of Q705K with a heterozygous C10X background. The
increased IL-1b and IL-18 cytokine levels obtained upon retroviral
expression of the Q705K into THP-1 cells indicate that it is a gain-
of-function variation leading to an overactive inflammasome. The
moderately produced IL-1b levels from NLRP3-Q705K (com-
pared to the MWS-causing NLRP3-R260W) suggest an important
role of this common variant in chronic inflammatory diseases. In
line with previous reports, we observed lower transduction
efficiencies in both the mutant variants, reflecting the induction
of inflammasome-linked cell death [24,25,26]. However, since the
caspase-1 inhibitor Z-YVAD-FMK effectively reduced IL-1b
levels, we can rule out the possibility that the produced IL-1b
was a result of pyronecrosis, which previously has been shown to
be caspase-1 independent [26]. Although using the same cell line
and constructs as in a previous report [24], we observed lower IL-
1b levels, which can likely be attributed to lab variations in
handling of cells and methods. CARD-8 has been suggested to be
a binding partner of NLRP3 but its functional role for
inflammasome function is not clear. A recent study using THP-1
cells showed that knocking-down CARD-8 did not affect IL-1b
production in response to influenza virus [27]. However, given the
inhibitory role of CARD-8 in the regulation of NF-kB [28], it is
possible that the lower amounts of functional CARD-8, as would
be the case with the truncating C10X mutation, results in a more
pronounced effect of any activating NLRP3 mutation. The relative
contribution of CARD-8-C10X to inflammatory disorders in
association with inflammasome mutations requires thorough
investigation and will hence be the subject of a separate study.
As a trigger for sterile inflammation we used alum, which is one
of the most widely used vaccine adjuvants and a known activator
of the NLRP3 inflammasome, to investigate the release of
cytokines from THP-1 cells expressing wild type and mutated
NLRP3 [13,15]. Indeed, we found that mutated NLRP3 produced
more cytokines in response to alum as compared to wild type
NLRP3. These findings suggest that the NLRP3-Q705K variant is
associated with a lower threshold for inflammasome activation,
potentially implying an increased genetic susceptibility for
inflammatory stimuli in individuals possessing this variant. Further
confirmation of NLRP3-Q705K being a gain-of-function variant
was obtained when elevated spontaneous mRNA levels of pro-IL-
1b were detected in the THP-1 cells stably expressing this variant.
In agreement with a previous report suggesting TNF-a to be a late
event associated with IL-1b release [2], we could detect TNF-a in
cells stably expressing the mutant variants but not in the freshly
transduced cells. The increased TNF-a release was likely a
downstream effect of IL-1b release, since anakinra could block the
effect. The lack of significantly increased TNF-a release in the
NLRP3-Q705K compared to the WT expressing cells could
possibly be due to sub-threshold levels of IL-1b observed in this
polymorphic variant compared to the NLRP3-R260W. How
NLRP3-Q705K enhances IL-1b and TNF-a expression indepen-
dently of the IL-1R remains elusive, but the involvement of other
pathways cannot be ruled out. For instance, signalling through IL-
18R has been shown to activate NF-kB [29], which could lead to
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PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34977Figure 2. Alum-induced levels of cytokine production by NLRP3-tranduced THP-1 cells. THP-1 cells expressing NLRP3-Q705K, NLRP3-
R260W, NLRP3-WT were pre-treated with Z-YVAD-FMK (50 mM, 2 h) or anakinra (5 mg/mL, 1 h) and exposed to alum (130 mg/mL, 4 h). A, IL-1b, B, IL-
18 and C, TNF-a secretion levels in unstimulated, alum, Z-YVAD-FMK or anakinra treated THP-1 cells are shown. Data represents one independent
experiment, out of 2–5. Inset, Fold higher A, IL-1b, B, IL-18 and C, TNF-a in NLRP3-Q705K and NLRP3-R260W compared to NLRP3- WT. Data represent
mean 6 SEM of 4–5 independent experiments.
doi:10.1371/journal.pone.0034977.g002
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Alternatively, apoptotic speck-like protein (ASC), which is another
component of the inflammasome, might through activation by the
NLRP3-Q705K directly up-regulate NF-kB-regulated genes such
as pro-IL-1b and TNF-a independently of the IL-1R
[32,33,34,35].
A number of patients displaying either classical or atypical
CAPS, possessing NLRP3-Q705K alone or in combination with
other polymorphisms has previously been reported [4,6,36,37]
many of which have successfully been treated with anakinra
[4,6,25,37]. However, as all these patients do not fit into the
conventional CAPS phenotype, the interpretation of NLRP3-
Q705K presents a diagnostic challenge to the clinicians.
Nonetheless, IL-1b blockade has been successful in treating many
of these patients [4,6,25,37]. In a recent paper we have reported
four patients with inflammatory symptoms carrying the NLRP3-
Q705K in combination with CARD-8-C10X, where increased IL-
1b release from patient’s monocytes was observed [38].
Based upon our in vitro studies as well as earlier published
epidemiological data [8,9,10,11], we suggest that these polymor-
phisms, in conjunction with an environmental cue such as an
infection, or with other, yet unidentified genetic variations,
predispose for enhanced inflammation. Using a similar THP-1
cell model, we have earlier published data showing a novel
M299V mutation in NLRP3 to be functional [25]. The
contribution of environmental factors rather than additional
genetic alterations would explain the later-onset of symptoms in
some of the patients, compared to the neonatal to early onset in
most of the CAPS patients carrying the severe disease-causing
mutations [4]. A similar situation has been described in FMF
where the alteration MEFV-E148Q, referred to as a polymor-
phism due to its presence in 10% of asymptomatic individuals, is
detected in patients with milder symptoms [39]. In this case,
environmental factors are suggested as the responsible triggers of
inflammation [40,41]. Increasing numbers of studies showing
synergistic effects between polymorphisms in different genes
associated to autoinflammation are emerging [36,42,43], signify-
ing the need of a careful diagnosis of the patients possessing low-
penetrance alterations.
In many reports, TLR ligands are used to drive the production
of pro-IL-1b for efficient IL-1b release [14,44,45]. Here we
studied the response of the inflammasome under sterile conditions,
where no TLR ligands or other bacterial products were used to
enhance transcription of pro-IL-1b. Our study reinforces the
importance of IL-1b signalling through its receptor for effective
production of the same cytokine under sterile conditions, which
has previously been demonstrated in healthy individuals [46] as
well as in CAPS patients [47,48]. We also show that IL-1b release
precedes TNF-a release via binding to the IL-1R, and that
treatment with anakinra decreases both IL-1b and TNF- a
releases, which has earlier been shown to occur in vivo in mice [49].
It is possible that such a pro-inflammatory feedback loop, once
established through different exogenous and endogenous stimuli,
may be difficult to break in patients with alterations in the NLRP3
inflammasome.
The discovery of disease-causing mutations in NLRP3 has led to
the recognition of a connection between autoinflammatory
disorders and a dysregulated innate immunity. The molecular
mechanism for the constitutive phenotype of disease-causing
NLRP3 alterations is not known, but it is suggested that this is
due to structural instability leading to unprovoked association of
NLRP3 with its adaptor molecules, causing spontaneous IL-1b
production [4,50]. Our present data are in agreement with
previous results showing missense alterations in exon 3 of NLRP3
to be associated with increased IL-1b [23].
In summary, we report an increased activity of the NLRP3-
Q705K polymorphism as demonstrated by the increased sponta-
neous and stimulated release of cytokines under sterile conditions.
Our study points to the need of extending the conventional
categorization of patients with non-classical CAPS, at the same
time the risk for over-interpretation of this genotype can be
avoided with careful diagnosis. The option of IL-1 blockade might
be considered, particularly in the patients unresponsive to
standard treatments.
Materials and Methods
Site-Directed Mutagenesis
Mutant forms of NLRP3 (NM_004895.3) were generated by
site-specific mutagenesis of the wild type NLRP3 cloned into a
retroviral vector, pHSPG, tagged with Green Fluorescent Protein
Figure 3. Basal levels of mRNA expression of pro-IL-1b and
TNF-a genes represented as folds increase over NLRP3-WT.
Data represents Mean 6 SEM of 3 independent experiments performed
in triplicates.
doi:10.1371/journal.pone.0034977.g003
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pairs were used:
Q705K, Forward (F) - gacaccttgatatggtgaagtgtgtcctcccaagc &
Q705K, Reverse (R) – gcttgggaggacacacttcaccatatcaaggtgtc
R260W, (F) - ctatctgttctatatccactgttgggaggtgagccttgtgacacag &
R260W, (R) - ctgtgtcacaaggctcacctcccaacagtggatatagaacagatag
Genotyping
THP-1 cells (American Type Culture Collection, Rockville,
MD) were genotyped for Q705K and C10X alterations using
Taqman assays (C_25648615_10 and C_551339_10, respectively)
following the manufacturers protocol (Applied Biosystems, Carls-
bad, CA).
Cell lines
293T cells (American Type Culture Collection, Rockville, MD)
were cultured in DMEM with 10% FBS and penicillin/
streptomycin. THP-1 cells were cultured in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum (FBS)
and penicillin/streptomycin. The cells were maintained in a
humidified atmosphere of 5% CO2 at 37uC and passaged every
third day.
Retroviral Transductions
For packaging of virus particles, 293T cells were transfected
with plasmids encoding WT and mutant NLRP3, pGag-Pol and
pVSV-G encoding plasmids as described by Eliasson [51]. 48 h
after transfection, viral supernatants were collected. Viral
supernatants were titrated on 293T cells and in all the cases were
found to be higher than 1610
6 particles/ml. THP-1 cells
(0.5610
6) were transduced by suspending in one volume cell
culture medium plus one volume virus supernatant, after which
polybrene (Sigma-Aldrich,St. Louis, MO) was added at a final
concentration of 4 mg/mL. The virus/cell mixture was centrifuged
at 15006g for 1.5 h at room temperature. The supernatant was
replaced with fresh medium. After 48 h, the cell supernatant was
harvested and stored at 270u C for cytokine analysis. The cells
were subjected to flow cytometry on a FACScan (BD Biosciences,
Franklin Lakes, NJ) to determine the efficiency of transduction
based on GFP expression. GFP-positive THP-1 cells were sorted
by FACS, expanded under standard culture conditions and used
for the cell stimulation assays.
Blockade of caspase-1 and IL-1
To investigate the role of caspase-1 in Q705K induced IL-1
production, 50 mM caspase-1 inhibitor Z-YVAD-FMK (Cayman
Chemicals, Ann Arbor, Michigan) was added to the cell culture
medium during the 48 hour retroviral transduction or 2 h prior to
addition of stimuli as indicated.
To more specifically assess the role of IL-1R blockade on
cytokine production, the IL-1R antagonist anakinra (Kineret,
Amgen, Thousand Oaks, CA) was added to a final concentration
of 5 mg/mL in the incubation medium 1 hr before the addition of
stimuli.
Stimulations
THP-1 cells stably expressing WT and mutant forms of NLRP3
were grown to a density of 1.5610
6/mL in cell culture flasks. 24 h
before stimulations, the cells were differentiated by treatment with
0.5 mM phorbol 12-myrsitate 13-acetate (PMA; Sigma-Aldrich) for
3 h. The cells were then washed with PBS and seeded at a density
of of 1610
6 cells/well in 12-well plates in standard RPMI
medium. The next day, cells were washed with PBS and 1 mL
RPMI medium was added. Aluminium Hydrogel (Alum; Sigma-
Aldrich) was used at 130 mg/mL for 4 h to stimulate the cells.
Detection of cytokines
The cytokines IL-1b, IL-18 and TNF-a were assessed in the cell
culture media using ELISA. The lower detection limit of IL-1b
and IL-18 (R&D systems, Minneapolis, MN and MBL Interna-
tional) were 0.16 pg/mL and 12.5 pg/mL, respectively, while that
for TNF-a (Abcam, Cambridge, MA) was 25 pg/mL.
Gene Expression
Total RNA was isolated from THP-1 cells using TRIzolH
(Invitrogen) and reverse transcribed to cDNA with Superscript II
(Invitrogen) following the recommended protocol. mRNA expres-
sion of pro-IL-1b, F-cctgcgtgttgaaagatgat & R-actgggcagact-
caaattcc and TNF-a F-cagagggcctgtacctcatc & R-gaggtt-
gaccttggtctggt, were determined in triplicates using the SYBR
green PCR kit on the 7900HT sequence detection system (Applied
Biosystems, Carlsbad, CA), b-actin, F-acccagcacaatgaagatca & R-
tcgtcatactcctgcttgct, was used for samples normalization and Ct
values were calculated using the 2
2
‘‘ct method.
Statistical methods
Data are represented as mean 6 SEM in figures 1, 2, 3.
Statistical comparisons were performed by Student’s unpaired t
test (figure 1) or two-way ANOVA with Tukey’s correction
(figures 2) using the software package SPSS 18.0. * represents P
values,0.05, ** represents P values,0.01 and *** represents P
values,0.001.
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